Gastritis Associated With Helicobacter Pylori Clinical Trial
Official title:
Comparison of Dual Amoxicillin/Vonoprazan Therapy and Triple Vonoprazan/Amoxicillin/Clarithromycin or Metronidazole Therapy for H. Pylori Eradication
Patients infected with H. pylori were randomly assigned to the dual therapy with vonoprazan 20 mg bid and amoxicillin 500 mg tid for 1 week or the triple therapy with vonoprazan 20 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg or metronidazole 250 mg bid bid for 1 week. Success or failure of eradication was determined by the 13C-urea breath test performed at 1 month after the therapy.
Patients infected with H. pylori were enrolled and invited to the study.
Patients who have never undergone the H. pylori eradication therapy are randomly assigned to
the dual therapy with vonoprazan 20 mg bid and amoxicillin 500 mg tid for 1 week or the
triple therapy with vonoprazan 20 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg
bid for 1 week.
Patients who have ever failed in the eradication of H. pylori by the triple therapy
containing clarithromycin are randomly assigned to the dual therapy with vonoprazan 20 mg bid
and amoxicillin 500 mg tid for 1 week or the triple therapy with vonoprazan 20 mg bid,
amoxicillin 750 mg bid and metronidazole 250 mg bid for 1 week.
Success or failure of eradication was determined by the 13C-urea breath test performed at 1
month after the therapy.
;